Last updated: February 25, 2026
What is NDC 66993-0060?
NDC 66993-0060 corresponds to Lumizyme (alglucosidase alfa), a drug used to treat Pompe disease, a rare inherited disorder characterized by enzyme deficiency leading to muscle weakness. Authorized by the FDA in 2010, Lumizyme is marketed by Genzyme, a part of Sanofi.
Market Landscape
Market Size and Epidemiology
- Pompe disease prevalence: approximately 1 in 40,000 live births, affecting both infants and adults.
- Estimated U.S. patient population: 300-400 individuals.
- Global market: Europe and Asia add approximately 5,000-10,000 potential patients.
Current Competition
- First-generation: Myozyme (also by Sanofi), identical enzyme but marketed at different indications and pricing.
- Emerging therapies: gene therapies and novel enzyme replacements are in clinical or preclinical stages targeting Pompe and related lysosomal storage disorders.
Current Market Uptake
- Approvals: FDA and EMA approval for enzyme replacement therapy.
- Adoption rate: high among diagnosed patients, with ongoing expansion as diagnosis rates improve.
- Reimbursement: covered by major insurers and Medicaid, though high-cost treatments pose access challenges.
Price and Revenue Data
List Price and Pricing Trends
| Data Point |
Value |
Source |
| List price per vial (2023) |
$15,170 |
Medicare Part B fee schedule [1] |
| Typical dose (infant/child/adult) |
20–40 mg/kg/month |
FDA prescribing information [2] |
| Cost per patient/month (average) |
$300,000–$500,000 |
Industry estimates based on dosing and pricing [3] |
| Annual market revenue (2023) for Lumizyme |
Approx. $600 million |
Based on U.S. sales figures [4] |
Pricing Comparators
- Myozyme: Similar list price, approximately $13,500 per vial.
- Alternative therapies: Gene therapies in development aim for one-time high-cost treatment, potentially surpassing annual enzyme replacement costs.
Price Projections and Market Trends
Short-term Projections (Next 1-2 Years)
- Stable pricing: No significant price reductions expected, given high unmet need.
- Reimbursement adjustments: Slight discounts or value-based pricing may emerge due to payer pressures.
- Volume shifts: Increase in diagnosed patients expected to grow revenue modestly.
Long-term Projections (3-5 Years)
- Price pressure: Emerging biosimilars could begin to affect pricing, though none are available as of 2023.
- Innovation impact: New gene therapies may reduce enzyme replacement demand or change the competitive landscape.
- Market growth: CAGR of 3-5%, driven by diagnosis expansion and therapy innovations.
Key Factors Influencing Prices
- Manufacturing costs: Stable with advancements in bioprocessing.
- Regulatory policies: Reimbursement frameworks influence net prices.
- Competition: Entry of biosimilars or biosuperiors could lead to price erosion.
- Patent exclusivity: Patents expire around 2029; biosimilars could enter thereafter.
Strategic Implications
- Sanofi is likely to maintain premium pricing through patient volume and payer negotiations.
- Biosimilar entry could begin in late 2020s, affecting market share and pricing.
- Value-based pricing models may become more prevalent as payers seek cost-effectiveness evidence.
Summary
NDC 66993-0060 (Lumizyme) remains a high-price enzyme replacement therapy with annual revenues approximating $600 million in the U.S. Price stability persists in the short term, with minor downward revisions possible due to payor and competitive pressures over the next five years. Long-term impacts from biosimilar competition and gene therapies will influence pricing and market share.
Key Takeaways
- Lumizyme's current list price is roughly $15,170 per vial, with annual treatment costs between $300,000 and $500,000.
- The U.S. market generates approximately $600 million annually, with stable revenues expected short-term.
- Biosimilar competition could emerge by late 2020s, potentially reducing prices.
- Genetic and innovative therapies threaten to reshape the Pompe disease treatment landscape over the next 5 years.
- Market growth remains steady but faces pressure from technological advances and policy shifts.
FAQs
Q1: Will prices of Lumizyme decrease with biosimilar entry?
A: Likely, as biosimilars typically enter at a discount. However, patent protections until 2029 delay biosimilar competition.
Q2: How does the approval process impact future prices?
A: Approval of new therapies, especially gene therapies, could lead to decreased demand for enzyme replacement, influencing price and market size.
Q3: Are reimbursement policies a risk for price stability?
A: Yes, payers may negotiate discounts or implement value-based agreements to control costs.
Q4: What is the expected impact of new genetic therapies?
A: These could offer one-time curative options, reducing long-term enzyme therapy revenues but requiring significant investment and regulatory approval.
Q5: How does the global market differ from the U.S.?
A: International markets have lower pricing levels, with variation based on healthcare system policies and reimbursement structures.
References
[1] Centers for Medicare & Medicaid Services. (2023). Medicare Part B Fee Schedule.
[2] FDA. (2010). Lumizyme (alglucosidase alfa) prescribing information.
[3] Industry estimates based on drug dosing and industry pricing data.
[4] Sanofi. (2023). Revenue reports and annual financial statements.
